Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March.
The item "Price-Earnings-Ratio" stands at 4.06 as of 09/30/2025.
As of the end of Sumitomo Dainippon Pharma Co Ltd's second quarter, the item "Price Earnings Ratio" stands at 4.06. This represents a decrease of -80.58 percent compared to it's value at the end of it's first quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 4.95 compared to the value the year prior.
The Serie's long term average value is 1.67. It's latest available value, on 09/30/2025, is 2.39 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 12/31/2022, to it's latest available value, on 09/30/2025, is +50.64 .
The Serie's change from it's maximum value, on 09/30/2022, to it's latest available value, on 09/30/2025, is -27.84 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price Earnings Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Price Earnings Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Price Earnings Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Price Earnings Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price Earnings Ratio | 280,205,508,085.11 |